197 related articles for article (PubMed ID: 17534183)
21. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
[TBL] [Abstract][Full Text] [Related]
23. Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
van den Heuvel MM; Korse CM; Bonfrer JM; Baas P
Lung Cancer; 2008 Mar; 59(3):350-4. PubMed ID: 17933420
[TBL] [Abstract][Full Text] [Related]
24. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
25. [Management of pleural disease].
Rodríguez-Panadero F; Pérez MA; Moya MA; Cruz MI
Arch Bronconeumol; 2009; 45 Suppl 3():22-7. PubMed ID: 20116740
[TBL] [Abstract][Full Text] [Related]
26. Malignant mesothelioma 2008.
Zervos MD; Bizekis C; Pass HI
Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R
Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560
[TBL] [Abstract][Full Text] [Related]
28. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
30. Soluble markers for diagnosis of malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
[TBL] [Abstract][Full Text] [Related]
31. Podoplanin as a marker for mesothelioma.
Kimura N; Kimura I
Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
[TBL] [Abstract][Full Text] [Related]
32. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Landi D; Gemignani F; Landi S
Occup Environ Med; 2010 Apr; 67(4):233-6. PubMed ID: 19858537
[TBL] [Abstract][Full Text] [Related]
35. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
36. Molecular biomarkers in malignant mesothelioma: state of the art.
Kao SC; Reid G; van Zandwijk N; Henderson DW; Klebe S
Pathology; 2011 Apr; 43(3):201-12. PubMed ID: 21436629
[TBL] [Abstract][Full Text] [Related]
37. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
38. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
39. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
40. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
Amati M; Tomasetti M; Mariotti L; Tarquini LM; Valentino M; Santarelli L
Mutat Res; 2008; 655(1-2):52-8. PubMed ID: 18638565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
